Prof Edith Perez speaks to ecancer at BGICC 2019 in Cairo about a debate covering the testing of Next Generation Sequencing in metastatic breast cancer patients. 

She argues for the side of 'yes', because of the potential benefits of precision and personalised medicine.

Prof Perez emphasises that the potential for NGS goes further than what we currently know, and by collaborating using improved data sharing methods, we can unlock better treatments.

See the opposing view from Prof Matti Aapro here.